Navigation Links
Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
Date:7/31/2008

LOS ANGELES, July 31 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Raptor Pharmaceuticals Corp. "Raptor's drug candidates, which target billion dollar markets, are progressing through the clinic at a rapid pace. The Company will present Phase 2 results for Convivia(TM) sometime in the 3rd quarter of 2008 and we expect FDA approval of Delayed Release (DR) Cysteamine for the treatment of cystinosis in 2010," stated Ross Silver, Director of Research for Vista Partners. For more information and to download the report for free, please visit the Vista Partners website at http://www.vistap.com and click on the "download research" icon.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Raptor:

Raptor Pharmaceuticals Corp. ("Raptor") is a development-stage biopharmaceutical company leveraging novel drug-targeting platforms and reformulated therapeutics to improve treatment outcomes among patients with liver disorders, infectious diseases, cancer, and various orphan indications. The Company's clinical division advances internally developed and in-licensed clinical-stage product candidates towards marketing approval and commercialization and is currently involved in clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency as part of Raptor's Convivia(TM) program and nephropathic cystinosis as part of Raptor's DR Cysteamine program. Raptor's preclinical division
'/>"/>

SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
3. Synvista Therapeutics to Present at the BIO InvestorForum 2007
4. Synvista Therapeutics to be Featured on Wallst.net
5. Provista Awards Agreement to Spheris
6. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
9. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
10. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
11. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ANN ARBOR, Mich. and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... NSF International, a leading provider of regulatory compliance, quality systems, ... acquired Avarent LLC, a consulting firm with expertise in medical device products/processes ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ) ... "Gene Therapy - Technologies, Markets and Companies" ... therapy are difficult to estimate as there is only ... in China since 2004. Gene ... estimates are based on epidemiology of diseases to be ...
(Date:9/2/2015)... , Sept. 2, 2015 Australian prostate ... a prestigious Australian science prize recognising ,outstanding, science that ... track to globally launch a novel prostate cancer diagnostic ... a high level consortium taking out the peer-reviewed Australian ... Scientific Research. This prize is awarded ...
(Date:9/2/2015)... Virginia , September 2, 2015 ... der Gewinner des Wettbewerbs BeHEARD von 2015 bekanntgeben ... internationalen vom Rare Genomics Institute. Biovista ... von Medikamenten für die Behandlung anderer Krankheiten als ... Steven Laffoon und sein Team bei ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... ... Reserve, ATLANTA, Jan. 21 ... center in the southeast to offer,the Repromedix Plan Ahead(TM) test, an innovative ... multiple factors,including the measurement of ovary-related hormones AMH, Inhibin B, and,FSH. The ...
... diuretic hydrochlorothiazide (HCTZ) in a ... significant additional blood pressure reductions compared to either drug alone ... more, medicines - single-tablet combinations simplify treatment by reducing ... number of pills patients take, EAST HANOVER, ...
... 18 The San Diego Consortium for,Regenerative Medicine ... score in three of four categories from the ... of the Major Facilities Grant,Application., SDCRM,s application, ... for basic research and discovery, 95 for preclinical ...
Cached Biology Technology:Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Women's Biological Clock 2Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Women's Biological Clock 3Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 2Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 3Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 4Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure 5SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application 2SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application 3
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. ... human interface solutions, today announced that four of ... Match-in-Sensor solution, have officially been named FIDO Certified™ ... part of the certification, Synaptics, Natural ID™ fingerprint ... Universal Authentication Framework (UAF) standard and are interoperable ...
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
(Date:8/5/2015)... ALBANY, New York , August 5, 2015 /PRNewswire/ ... new market report titled "Facial Recognition Market - Global ... - 2022", the global market for facial recognition is ... market is driven by increased demand for surveillance systems ... to the rising number of crimes and terrorist activities ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... one simple premise: when given a choice between two items, ... value more. But as with many simple premises, this one ... The fields of psychology and behavioral economics have experimentally identified ... act against their own apparent interests. One of these biases ...
... time, researchers have been able to map the true extent ... De Dios in the Peruvian Amazon. The team combined field ... that the geographic extent of mining has increased 400% from ... forest loss has tripled since the Great Recession of 2008. ...
... Ill. In the chemical age of agriculture that began ... referred to as potash, is widely used as a major ... soil reserves that were once recognized for their fundamental importance ... serious concerns with the current approach to potassium management that ...
Cached Biology News:Common bias known as the 'endowment effect' not present in hunter-gatherer societies 2Common bias known as the 'endowment effect' not present in hunter-gatherer societies 3Common bias known as the 'endowment effect' not present in hunter-gatherer societies 4Gold mining ravages Peru 2Gold mining ravages Peru 3Study challenges soil testing for potassium and the fertilizer value of potassium chloride 2Study challenges soil testing for potassium and the fertilizer value of potassium chloride 3Study challenges soil testing for potassium and the fertilizer value of potassium chloride 4
... NaCl, 20mM MOPS, pH 7.5, 60mM ... EGTA, 10 Properites: For selective in ... chromatography, divalent cation activation plus trypsin ... Assurance: routinely evaluated by dephosphorylation of ...
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
Biology Products: